September 11, 2024 – FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can potentially improve patient outcome.
Tag: antibody
FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies
April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.